Introduction: New-generation drug-eluting stents (DES) represent the current standard of
care in patients undergoing percutaneous coronary intervention (PCI). Biodegradable …

Dual antiplatelet therapy (DAPT) is mandatory after percutaneous coronary intervention
(PCI) with drug-eluting stent (DES) implantation, but optimal DAPT duration remains a topic …

Drug-eluting stents (DES) have been shown to significantly reduce clinical and angiographic
restenosis compared to bare metal stents (BMS). The polymer coatings on DES elute …

We characterized the performance as well as safety of a second-generation thin-strut
sirolimus-eluting stent with a biodegradable polymer, Alex Plus (Balton, Poland), deployed …

This study aimed to compare the strut coverage between Orsiro ultrathin struts
biodegradable polymer sirolimus-eluting stents (O-SES) and Xience thin struts durable …

Aims Bioresorbable polymer drug-eluting stent technologies have been considered to have
the potential to enhance vascular healing by reducing polymer exposure to the vessel wall …

Aims We aimed to corroborate clinical evidence on the safety and efficacy of the ultrathin-
strut biodegradable-polymer sirolimus-eluting Orsiro stent in an all-comer population …

Background Bioresorbable-polymer drug-eluting stent (BP-DES) demonstrates comparable
clinical outcomes compared to durable-polymer drug-eluting stent (DP-DES). However …

In‐stent neoatherosclerosis (NA), characterized by a relatively thin fibrous cap and large
volume of yellow‐lipid accumulation after drug‐eluting stents (DES) implantation, has …

Aims Whether biodegradable-polymer drug-eluting stents (BP-DES) induce a vascular
response at follow-up more favourable than that of new-generation durable-polymer drug …